| Literature DB >> 33936238 |
Minglong Guan1,2,3, Lan Guo4, Hengli Ma1,2,3, Huimei Wu1,2,3, Xiaoyun Fan1,2,3.
Abstract
Rosmarinic acid (RosA) is a natural phenolic acid compound, which is mainly extracted from Labiatae and Arnebia. At present, there is no systematic analysis of its mechanism. Therefore, we used the method of network pharmacology to analyze the mechanism of RosA. In our study, PubChem database was used to search for the chemical formula and the Chemical Abstracts Service (CAS) number of RosA. Then, the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) was used to evaluate the pharmacodynamics of RosA, and the Comparative Toxicogenomics Database (CTD) was used to identify the potential target genes of RosA. In addition, the Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of target genes were carried out by using the web-based gene set analysis toolkit (WebGestalt). At the same time, we uploaded the targets to the STRING database to obtain the protein interaction network. Then, we carried out a molecular docking about targets and RosA. Finally, we used Cytoscape to establish a visual protein-protein interaction network and drug-target-pathway network and analyze these networks. Our data showed that RosA has good biological activity and drug utilization. There are 55 target genes that have been identified. Then, the bioinformatics analysis and network analysis found that these target genes are closely related to inflammatory response, tumor occurrence and development, and other biological processes. These results demonstrated that RosA can act on a variety of proteins and pathways to form a systematic pharmacological network, which has good value in drug development and utilization.Entities:
Year: 2021 PMID: 33936238 PMCID: PMC8055417 DOI: 10.1155/2021/5190808
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1(a) Molecular structural formula of rosmarinic acid (PubChem CID: 5281792). (b) The flow of bioinformatics analysis of RosA includes target gene prediction, ADME evaluation, GO enrichment analysis, KEGG enrichment analysis, the construction of protein-protein interaction network, the construction of the drug-target-pathway network, and molecular docking.
Pharmacological and molecular properties data of RosA.
| Name | MW | AlogP | OB (%) | Caco-2 | BBB | DL | RBN |
|---|---|---|---|---|---|---|---|
| RosA | 360.34 | 2.69 | 1.38 | −0.54 | −1.24 | 0.35 | 7 |
MW, molecular weight; Caco-2, caco-2 permeability; OB, oral bioavailability; DL, drug-likeness; BBB, blood-brain barrier.
Target genes of RosA from CTD database.
| No. | Gene ID | Gene symbol | Description |
|---|---|---|---|
| 1 | 10544 | PROCR | Protein C receptor |
| 2 | 6868 | Adam17 | Adam metallopeptidase domain 17 |
| 3 | 5970 | RELA | RELA proto-oncogene, NF-kB subunit |
| 4 | 7040 | TGFB1 | Transforming growth factor beta 1 |
| 5 | 7124 | TNF | Tumor necrosis factor |
| 6 | 3553 | IL1B | Interleukin 1 beta |
| 7 | 3569 | IL6 | Interleukin 6 |
| 8 | 5468 | PPARG | Peroxisome proliferator-activated receptor gamma |
| 9 | 847 | CAT | Catalase |
| 10 | 4780 | NFE2L2 | Nuclear factor, erythroid 2 like 2 |
| 11 | 1277 | COL1A1 | Collagen type I alpha 1 chain |
| 12 | 1401 | CRP | C-reactive protein |
| 13 | 2919 | CXCL1 | C-X-C motif chemokine ligand 1 |
| 14 | 59 | ACTA2 | Actin alpha 2, smooth muscle |
| 15 | 836 | CASP3 | Caspase 3 |
| 16 | 1490 | CCN2 | Cellular communication network factor 2 |
| 17 | 1281 | COL3A1 | Collagen type III alpha 1 chain |
| 18 | 2876 | GPX1 | Glutathione peroxidase 1 |
| 19 | 9446 | GSTO1 | Glutathione S-transferase omega 1 |
| 20 | 3162 | HMOX1 | Heme oxygenase 1 |
| 21 | 9817 | KEAP1 | Kelch-like ECH-associated protein 1 |
| 22 | 4313 | MMP2 | Matrix metallopeptidase 2 |
| 23 | 4318 | MMP9 | Matrix metallopeptidase 9 |
| 24 | 4843 | NOS2 | Nitric oxide synthase 2 |
| 25 | 1728 | NQO1 | NAD(P)H-quinone dehydrogenase 1 |
| 26 | 5054 | SERPINE1 | Serpin family |
| 27 | 6647 | SOD1 | Superoxide dismutase 1 |
| 28 | 6648 | SOD2 | Superoxide dismutase 2 |
| 29 | 7498 | XDH | Xanthine dehydrogenase |
| 30 | 9131 | AIFM1 | Apoptosis inducing factor mitochondria associated 1 |
| 31 | 595 | CCND1 | Cyclin D1 |
| 32 | 968 | CD68 | CD68 molecule |
| 33 | 1312 | COMT | catechol-O-methyltransferase |
| 34 | 1674 | DES | Desmin |
| 35 | 1786 | DNMT1 | DNA methyltransferase 1 |
| 36 | 2335 | FN1 | Fibronectin 1 |
| 37 | 2353 | FOS | Fos proto-oncogene, AP-1 transcription factor subunit |
| 38 | 2875 | GPT | Glutamic--pyruvic transaminase |
| 39 | 3146 | HMGB1 | High mobility group box 1 |
| 40 | 3725 | JUN | Jun proto-oncogene, AP-1 transcription factor subunit |
| 41 | 157855 | KCNU1 | Potassium calcium-activated channel subfamily U member 1 |
| 42 | 4128 | MAOA | Monoamine oxidase A |
| 43 | 4129 | MAOB | Monoamine oxidase B |
| 44 | 6885 | MAP3K7 | Mitogen-activated protein kinase kinase kinase 7 |
| 45 | 5594 | MAPK1 | Mitogen-activated protein kinase 1 |
| 46 | 5595 | MAPK3 | Mitogen-activated protein kinase 3 |
| 47 | 5599 | MAPK8 | Mitogen-activated protein kinase 8 |
| 48 | 5601 | MAPK9 | Mitogen-activated protein kinase 9 |
| 49 | 4353 | MPO | Myeloperoxidase |
| 50 | 4615 | MYD88 | MYD88 innate immune signal transduction adaptor |
| 51 | 4846 | NOS3 | Nitric oxide synthase 3 |
| 52 | 4968 | OGG1 | 8-Oxoguanine DNA glycosylase |
| 53 | 8505 | PARG | Poly (ADP-ribose) glycohydrolase |
| 54 | 7099 | TLR4 | Toll-like receptor 4 |
| 55 | 7431 | VIM | Vimentin |
Figure 2Protein interaction network of RosA target genes.
Key protein topological parameters of protein interaction network.
| Name | Degree | Betweenness centrality | Closeness centrality |
|---|---|---|---|
| TNF | 53 | 0.06924682 | 0.8630137 |
| IL6 | 51 | 0.05915435 | 0.84 |
| CASP3 | 49 | 0.08868983 | 0.81818182 |
| JUN | 46 | 0.03570932 | 0.7875 |
| MAPK8 | 44 | 0.02681408 | 0.76829268 |
| IL1B | 42 | 0.01914187 | 0.75 |
| MMP9 | 42 | 0.02381611 | 0.75 |
| MAPK3 | 41 | 0.01732055 | 0.74117647 |
| TLR4 | 40 | 0.01981721 | 0.73255814 |
| CAT | 38 | 0.07900048 | 0.71590909 |
| MAPK1 | 38 | 0.0134504 | 0.71590909 |
| HMOX1 | 36 | 0.01175721 | 0.7 |
| FN1 | 36 | 0.01346746 | 0.7 |
| FOS | 34 | 0.02316259 | 0.68478261 |
| TGFB1 | 34 | 0.03713298 | 0.68478261 |
| SERPINE1 | 31 | 0.01151125 | 0.66315789 |
| SOD2 | 30 | 0.03539503 | 0.64948454 |
| NQO1 | 24 | 0.01251491 | 0.61165049 |
Figure 3GO enrichment summary of the target genes. Biological process (BP), cellular component (CC), and molecular function (MF) are expressed by red (a), blue (b), and green (c), respectively. The height of the bar represents the number of target genes.
Figure 4KEGG enrichment analysis of target genes.
Figure 5Compound (RosA)-target-pathway network.
Compound-target molecular docking binding energy.
| No. | Targets | Compound | Binding energy (kJ/mol) |
|---|---|---|---|
| 1 | MMP9 | RosA | −7.76 |
| 2 | MAPK3 | −7.71 | |
| 3 | JUN | −6.83 | |
| 4 | CAT | −6.68 | |
| 5 | SERPINE1 | −6.61 | |
| 6 | MAPK8 | −6.16 | |
| 7 | FN1 | −6.09 | |
| 8 | FOS | −6.02 | |
| 9 | TGFB1 | −5.87 | |
| 10 | TNF | −5.73 | |
| 11 | MAPK1 | −5.57 | |
| 12 | TLR4 | −5.5 | |
| 13 | IL1B | −5.31 | |
| 14 | NQO1 | −4.76 | |
| 15 | CASP3 | −4.73 | |
| 16 | SOD2 | −4.72 | |
| 17 | HMOX1 | −4.34 | |
| 18 | IL6 | −3.55 |
Figure 63D and 2D pictures of the four best docking results. (a) MMP9 and RosA; (b) MAPK3 and RosA; (c) JUN and RosA; (d) CAT and RosA.